Paclitaxel-induced hepatic steatosis in patients with breast cancer

dc.contributor.authorInci, Fatih
dc.contributor.authorKaratas, Fatih
dc.date.accessioned2024-09-29T16:11:40Z
dc.date.available2024-09-29T16:11:40Z
dc.date.issued2019
dc.departmentKarabük Üniversitesien_US
dc.description.abstractPurpose: Paclitaxel has been associated with serum aminotransferase elevations, however, paclitaxel induced hepatosteatosis has not been evaluated systematically. This study assessed the rate of paclitaxel-related hepatosteatosis. Methods: Forty one early breast cancer (BC) patients were included the study. Hepatic ultrasonograpy, demographic features and biochemical liver function tests before and after 12 weeks of paclitaxel were assessed. Results: New-onset hepatosteatosis was developed in 26.7% of the patients. Baseline triglyceride>200mg/dL (OR, 11.25; p=0.015), LDH at baseline > 191.48 IU/L (OR, 4.93; p=0.048), and total bilirubin >0.51 mg/dL after paditaxel (OR, 6.17; p=0.042) were found as independent prognostic markers for new-onset hepatosteatosis. Conclusion: Paclitaxel may induce hepatosteatosis in patients with BC.en_US
dc.identifier.endpage2360en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue6en_US
dc.identifier.pmid31983106en_US
dc.identifier.startpage2355en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14619/8621
dc.identifier.volume24en_US
dc.identifier.wosWOS:000503405400022en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectpaclitaxelen_US
dc.subjecthepatosteatosisen_US
dc.subjectbreast canceren_US
dc.titlePaclitaxel-induced hepatic steatosis in patients with breast canceren_US
dc.typeArticleen_US

Dosyalar